Cargando…
Antileukemic activity of novel adenosine derivatives
The present study investigated the effect of cladribine (CLA) and six of its derivatives containing a formamidine group at position 6 (CLA-FDM, CLA-FPAZ, CLA-FPIR, CLA-FPIP, CLA-FHEX, and CLA-FMOR) on acute promyelocytic, lymphoblastic, and acute monocytic leukemia cells. The role of ATR kinase in d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773697/ https://www.ncbi.nlm.nih.gov/pubmed/31575977 http://dx.doi.org/10.1038/s41598-019-50509-1 |
_version_ | 1783455931129921536 |
---|---|
author | Poczta, Anastazja Rogalska, Aneta Łukawska, Małgorzata Marczak, Agnieszka |
author_facet | Poczta, Anastazja Rogalska, Aneta Łukawska, Małgorzata Marczak, Agnieszka |
author_sort | Poczta, Anastazja |
collection | PubMed |
description | The present study investigated the effect of cladribine (CLA) and six of its derivatives containing a formamidine group at position 6 (CLA-FDM, CLA-FPAZ, CLA-FPIR, CLA-FPIP, CLA-FHEX, and CLA-FMOR) on acute promyelocytic, lymphoblastic, and acute monocytic leukemia cells. The role of ATR kinase in deoxycytidine kinase (dCK) activation in response to DNA damage was assessed. The presence of DNA lesions was assessed by measurement phosphorylation of H2AX and by using the alkaline comet assay with proteinase K post-treatment following assessment of the cell cycle. Apoptotic events such as alterations in intracellular calcium concentration, caspase-3/7 activity and increased sub-G1 cell population were measured. CLA derivatives were highly effective against leukemic cells, showing high cytotoxicity, causing DNA fragmentation, and inducing DNA-protein cross-links in leukemic cells. CLA-FMOR showed the highest efficacy. CLA derivatives increased the levels of intracellular calcium ions, caspase-3/7 and the percentage of sub-G1 apoptotic cells and blocked cells in the S phase of the cell cycle to a greater extent than free CLA. The selective ATR inhibitor VE-821 significantly suppressed the increase in dCK activity and decreased basal dCK activity. The present results suggested that ATR kinase controls dCK activity in response to synthetic CLA derivatives. |
format | Online Article Text |
id | pubmed-6773697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67736972019-10-04 Antileukemic activity of novel adenosine derivatives Poczta, Anastazja Rogalska, Aneta Łukawska, Małgorzata Marczak, Agnieszka Sci Rep Article The present study investigated the effect of cladribine (CLA) and six of its derivatives containing a formamidine group at position 6 (CLA-FDM, CLA-FPAZ, CLA-FPIR, CLA-FPIP, CLA-FHEX, and CLA-FMOR) on acute promyelocytic, lymphoblastic, and acute monocytic leukemia cells. The role of ATR kinase in deoxycytidine kinase (dCK) activation in response to DNA damage was assessed. The presence of DNA lesions was assessed by measurement phosphorylation of H2AX and by using the alkaline comet assay with proteinase K post-treatment following assessment of the cell cycle. Apoptotic events such as alterations in intracellular calcium concentration, caspase-3/7 activity and increased sub-G1 cell population were measured. CLA derivatives were highly effective against leukemic cells, showing high cytotoxicity, causing DNA fragmentation, and inducing DNA-protein cross-links in leukemic cells. CLA-FMOR showed the highest efficacy. CLA derivatives increased the levels of intracellular calcium ions, caspase-3/7 and the percentage of sub-G1 apoptotic cells and blocked cells in the S phase of the cell cycle to a greater extent than free CLA. The selective ATR inhibitor VE-821 significantly suppressed the increase in dCK activity and decreased basal dCK activity. The present results suggested that ATR kinase controls dCK activity in response to synthetic CLA derivatives. Nature Publishing Group UK 2019-10-01 /pmc/articles/PMC6773697/ /pubmed/31575977 http://dx.doi.org/10.1038/s41598-019-50509-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Poczta, Anastazja Rogalska, Aneta Łukawska, Małgorzata Marczak, Agnieszka Antileukemic activity of novel adenosine derivatives |
title | Antileukemic activity of novel adenosine derivatives |
title_full | Antileukemic activity of novel adenosine derivatives |
title_fullStr | Antileukemic activity of novel adenosine derivatives |
title_full_unstemmed | Antileukemic activity of novel adenosine derivatives |
title_short | Antileukemic activity of novel adenosine derivatives |
title_sort | antileukemic activity of novel adenosine derivatives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773697/ https://www.ncbi.nlm.nih.gov/pubmed/31575977 http://dx.doi.org/10.1038/s41598-019-50509-1 |
work_keys_str_mv | AT pocztaanastazja antileukemicactivityofnoveladenosinederivatives AT rogalskaaneta antileukemicactivityofnoveladenosinederivatives AT łukawskamałgorzata antileukemicactivityofnoveladenosinederivatives AT marczakagnieszka antileukemicactivityofnoveladenosinederivatives |